Navigation Links
NeurogesX Reports Second Quarter 2009 Results
Date:8/7/2009

/li>
  • NGX-6052, the most advanced molecule synthesized in NeurogesX' opioid prodrug platform, has been evaluated in proof of concept in vivo and in vitro preclinical studies for its potential to deliver therapeutic efficacy with a potentially improved side effect profile and possible abuse-deterrent attributes.

    • Conference Call Details

    The Company will hold its quarterly conference call today at 9:00 a.m. ET (6:00 a.m. PT) to discuss second quarter 2009 results and recent corporate updates.

    To participate, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at http://www.neurogesx.com.

    A replay of the conference call will be available beginning August 7, 2009 at 12:00 p.m. ET (9:00 a.m. PT) and ending on August 17, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 329620. A replay of the webcast will also be available on the corporate website for one month, through September 7, 2009.

    About NeurogesX, Inc.

    NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenz
    '/>"/>

    SOURCE NeurogesX, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
    2. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
    3. NeurogesX Added to Russell 3000 Index
    4. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
    5. NeurogesX to Present at Needham Life Sciences Conference
    6. NeurogesX Receives European Commission Approval for Qutenza(TM)
    7. NeurogesX Reports First Quarter 2009 Results
    8. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
    9. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
    10. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
    11. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/19/2009)...World,s Top Gene Synthesis Companies Form Internat...te Best Practices in Risk Reduction ,Five Member...Synthesis Capacity , (PRW... leading gene synthesis companies today announced ...protocol to promote biosecurity in the gene synthe...
    (Date:11/18/2009)...eed to be able to find explosive materials and per...ch searches, the National Institute of Standards a...ment of Homeland Security, has developed a new cer...rial (SRM) 2905, Trace Particulate Explosives. Com...he SRM will be helpful in calibrating, testing and...
    (Date:11/18/2009)... Nov. 18 Masimo (Nasda...and Measure-Through Motion and Low-Perfusion pulse... Uni.H.A., one of the largest healthcare Group Pur...a multi-year purchasing agreement for "gold standa...ment offers preferred contract pricing to Uni.H.A....
    (Date:11/18/2009)...S, Fla., Nov. 18 Algenol Biofuels ...ogy, and the technology group The Linde Group ha...oject in order to identify the optimum management ...l,s unique algae and photobioreactor technology. T... to develop cost-efficient technologies that captu...
    Breaking Biology Technology:World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4New NIST trace explosives standard slated for homeland security duty 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 2Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 3
    ...artin Brand collaborate with Seahorse Bioscience, ...shop and will share their years of experience stud...ndees , , N. BILLERICA, Mass., May 29 Seahorse B...and consumables for cell based metabolic assays an...p, " Understanding When and How to Use Intact Cel...
    ...ully Delivered into the Bloodstream , , - Data De...evels of Oxycodone , , MELBOURNE, Australia, May ...POH; OTCQX: PPGNY) today announced the successful ...atented TPM/oxycodone transdermal patch system. Th...that by incorporating TPM/oxycodone into innovativ...
    ...29 Exiqon Diagnostics, announced today a strategi...innovative, comprehensive internet based solution ...eful knowledge on the latest topics in cancer trea...izing cancer care through novel molecular and cell...tory services, will become a content partner by pr...
    Other Biology Technology:New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 2New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 3Phosphagenics Announces Completion of Transdermal Patch Prototypes 2Phosphagenics Announces Completion of Transdermal Patch Prototypes 3Phosphagenics Announces Completion of Transdermal Patch Prototypes 4Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 2Exiqon Diagnostics Partners With MedTrust Online to Promote KRAS Mutation Analysis and Other Innovative Molecular Oncology Diagnostic Services to Oncologists 3
    (Date:11/19/2009)...end of the last ice age, North America,s vast asse...atures as mammoths, mastodons, camels, horses, gro...ous slide to extinction. , And when their popula...large animals equaled or surpassed Africa,s wildli...novel ecosystem emerged as broadleaved trees once ...
    (Date:11/19/2009)...lti-institutional effort co-led by three Cold Spri...today in publication of a landmark series of paper...ted detail the DNA sequence of maize ( Zea mays ).... American consumers, is one of the world,s most im...crop grown in the United States, representing $47 ...
    (Date:11/19/2009)...T. Ming Chu Professor of Biochemistry and Molecula...g how regulatory proteins control the production o...king with collaborators including Drs. Mitchell We...adelphia, they focused specifically on the complex...s). These cells contain large amounts of hemoglobi...
    Breaking Biology News(10 mins):After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4New research into the mechanisms of gene regulation 2New research into the mechanisms of gene regulation 3New research into the mechanisms of gene regulation 4New research into the mechanisms of gene regulation 5Hospital Corporation of America Recognized by InformationWeek as One of Nations Most Innovative Users of Business Technology 57262 1Hospital Corporation of America Recognized by InformationWeek as One of Nations Most Innovative Users of Business Technology 57262 2Weighing costs benefits of HIV treatments 57258 1Weighing costs benefits of HIV treatments 57258 2Weighing costs benefits of HIV treatments 57258 3New Web site promotes interoperable newborn screening data 9938 1New Web site promotes interoperable newborn screening data 9938 2
    ...2008) While pondering the challenges of distingui... mass of hundreds or thousands of nanoprobes, rese...an interesting observation. The tiny, clustered do...ear night. , The biomedical researchers realized ... solving a problem very similar to their own isol...
    ...e center of some of the nation,s most pressing cha... global climate change. To provide a critical over...emies are convening a summit of leading energy exp...nd the private sector. The event will inform an Ac...uture: Technology Opportunities, Risks, and Tradeo...
    ...ersity of York have characterised an important new...ur immune system. , It is an invisibility cloak ...zae, a common cause of ear infections in children,... attacked by the immune system. , A multidiscipl...y and Chemistry at York have been studying how bac...
    Other Biology News:Astronomy technology brings nanoparticle probes into sharper focus 2Astronomy technology brings nanoparticle probes into sharper focus 3NAS to hold 2-day summit on energy issues 2
    Mouse Anti-Yellow Fever Virus Monoclonal Antibody, Unconjugated, Clone 3576 from Abcam
    Mouse Anti-Human XPMC2H Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
    Gel Loading Dye (Bromophenol Blue/Glycerol) from Mo Bio Laboratories, Inc.
    Anti-JNK1 / SAPK Antibody, Unconjugated from Cell Sciences
    Biology Products: